CCC Diagnostics, LLC

CCC DIAGNOSTICS, LLC, 9039 FURROW AVE
Ellicott City, MD 21042

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $2.42MM
First Award Date 01/01/98
Most Recent Award Date 02/02/06

Key Personnel

Last Name Name Awards Contact
Ts'O Paul O. P. Ts'O 6
Rheinstein Peter H Rheinstein 2
Lesko Stephen Lesko 2

10 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-106
Budget: 02/02/06 - 11/30/07

DESCRIPTION (provided by applicant): Technology describing epithelial circulating cancer cells (CCC) was first established in Cell Works' Phase I study. This study was based on prostate cancer and has been expanded to include breast, colon, gastric, liver and pancreatic cancer with the same universal test protocol for all six epithelial cance...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-106
Budget: 12/01/04 - 11/30/05

DESCRIPTION (provided by applicant): Technology describing epithelial circulating cancer cells (CCC) was first established in Cell Works' Phase I study. This study was based on prostate cancer and has been expanded to include breast, colon, gastric, liver and pancreatic cancer with the same universal test protocol for all six epithelial cance...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-106
Budget: 07/01/04 - 11/30/04

DESCRIPTION (provided by applicant): Technology describing epithelial circulating cancer cells (CCC) was first established in Cell Works' Phase I study. This study was based on prostate cancer and has been expanded to include breast, colon, gastric, liver and pancreatic cancer with the same universal test protocol for all six epithelial cance...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-106
Budget: 12/30/03 - 06/30/04

DESCRIPTION (provided by applicant): Technology describing epithelial circulating cancer cells (CCC) was first established in Cell Works' Phase I study. This study was based on prostate cancer and has been expanded to include breast, colon, gastric, liver and pancreatic cancer with the same universal test protocol for all six epithelial cance...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-030
Budget: 09/01/02 - 08/31/03

DESCRIPTION: (Applicant's Description) The development of a ligand-directed, liver-specific, 5-flurouracil containing neoglycoconjugate is proposed for the treatment of hepatocellular carcinoma. This neoglycoconjugate is comprised of the liver-specific ligand YEE(ahG...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-00-030
Budget: 09/01/01 - 08/31/02

DESCRIPTION: (Applicant's Description) The development of a ligand-directed, liver-specific, 5-flurouracil containing neoglycoconjugate is proposed for the treatment of hepatocellular carcinoma. This neoglycoconjugate is comprised of the liver-specific ligand YEE(ahG...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-98-066
Budget: 05/01/99 - 10/31/99

The major long term goals of this project are 1) to standardize culture of cancer cells from individual prostate cancer patients, 2) to develop molecular profiling for cancer predictive characteristic such as chromosomal aneuploidy, circulating markers for cell proliferation and quiescence, androgen receptor gene copy. The molecular profiling is...

Phase 2 SBIR

Agency: National Science Foundation
Topic: 1999
Budget: 01/01/99 - 12/31/99

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 03/31/99

DESCRIPTION: Once cancer is diagnosed in a patient, surgical intervention is common to remove the malignant tumor. There are few clinical tests that can help physicians decide after surgery whether residual cancer cells remain in the body, and more importantly, whether these cells are inconsequential or aggr...

Phase 1 SBIR

Agency: National Science Foundation
Topic: 1998
Budget: 01/01/98 - 12/31/98

Load More